Bioavailability of BI 1356 After Single Oral Administration Given as Different Tablet Formulation in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BI 1356 - Tablet TFIIDrug: BI 1356 - Tablet iFFDrug: BI 1356 - Tablet TFIIb
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02183363
Bioavailability of BI 1356 After Co-administration With Ritonavir Compared to the Bioavailability of BI 1356 Alone in Healthy Male Volunteers
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT02183441
Efficacy and Safety of Oral Treatment With BIBF 1120 ES in Advanced Non-small-cell Lung Cancer
Phase 2
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Drug: BIBF 1120 ES high doseDrug: Placebo to BIBF 1120 ESDrug: BIBF 1120 ES low dose
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 73
- Registration Number
- NCT02182050
Efficacy and Safety Study of Meloxicam Versus Mefenamic Acid in Patients With Dysmenorrhea
Phase 2
Completed
- Conditions
- Dysmenorrhea
- Interventions
- Drug: Placebo matching 7.5 mg meloxicamDrug: Placebo matching 500 mg mefenamic acidDrug: Placebo matching 15 mg meloxicam
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 337
- Registration Number
- NCT02183025
Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 201335 NA in Healthy Male Subjects
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 39
- Registration Number
- NCT02182362
Safety and Tolerability Study of BIBF 1120 as Intravenous Infusion and Absolute Bioavailability of BIBF 1120 as Soft Gelatine Capsule in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BIBF 1120 intravenous solutionDrug: Placebo ampouleDrug: BIBF 1120 soft gelatine capsule
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT02182258
Single Rising Dose Study of BI 201335 ZW in Healthy Male Subjects
Phase 1
Terminated
- Conditions
- Healthy
- Interventions
- Drug: PlaceboDrug: BI 201335 ZW - single rising dose
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 8
- Registration Number
- NCT02182271
Assessment of the Effect of BI 201335 on the QT Interval in Healthy Female and Male Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 56
- Registration Number
- NCT02182310
Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine, Abacavir and Amprenavir in HIV-1 Infected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Naive Adults
Phase 1
Terminated
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 8
- Registration Number
- NCT02182765
Efficacy and Tolerability of Metamizol in Patients With Episodic Moderate Headache
Phase 3
Completed
- Conditions
- Migraine Disorders
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 417
- Registration Number
- NCT02183220